文献速递前列腺癌

70岁以上局限性临床显著前列腺癌患者局灶消融治疗结局评估:多机构、多能量15年经验

Evaluation of Outcomes Following Focal Ablative Therapy for Treatment of Localized Clinically Significant Prostate Cancer in Patients >70 Years: A Multi-institute, Multi-energy 15-Year Experience.
PubMed 文献 · J Urol · 2023-04-04

研究评估了英国11个中心649例70岁及以上接受局灶高强度聚焦超声或冷冻治疗的局限性前列腺癌患者,中位年龄74岁,中位随访24个月。5年无失败生存率为82%(95%CI:76%-87%),倾向评分加权分析显示根治治疗组5年无失败生存率为96%(95%CI:93%-100%),高于局灶治疗组的82%(95%CI:75%-91%)(P < .001)。作者提出局灶治疗可作为不适合或不愿接受根治治疗的老年或合并症患者的有效管理选择。

要点

  • 649例70岁及以上患者接受局灶高强度聚焦超声或冷冻治疗,5年无失败生存率为82%(95%CI:76%-87%)。
  • 倾向评分加权分析中根治治疗组5年无失败生存率96%(95%CI:93%-100%)高于局灶治疗组82%(95%CI:75%-91%)(P < .001)。
  • 作者提出局灶治疗可作为不适合或不愿接受根治治疗的老年或合并症患者的有效管理选择。

核心结论

  • 作者提出局灶治疗可作为不适合或不愿接受根治治疗的老年或合并症患者的有效管理选择。

研究设计与样本

  • 多机构、多能量15年经验研究,纳入英国11个中心2006年6月至2020年7月期间接受局灶高强度聚焦超声或冷冻治疗的649例患者,数据来自英国HEAT和ICE登记。
  • 主要结局为无失败生存,定义为需要超过1次局灶再消融、进展至根治治疗、发生转移、需要全身治疗或前列腺癌特异性死亡。
  • 通过与接受根治治疗的患者进行倾向评分加权分析进行比较。

主要发现

  • 中位年龄74岁(IQR:72,77),中位随访24个月(IQR:12,41)。
  • 60%患者为中危疾病,35%为高危疾病。
  • 113例患者(17%)需要进一步治疗,其中16例接受根治治疗,44例需要全身治疗。
  • 5年无失败生存率为82%(95%CI:76%-87%)。
  • 根治治疗组5年无失败生存率为96%(95%CI:93%-100%),局灶治疗组为82%(95%CI:75%-91%)(P < .001)。

临床怎么用

  • 作者提出局灶治疗可作为不适合或不愿接受根治治疗的老年或合并症患者的有效管理选择。

局限性

  • 根治治疗组中93%以放疗作为主要治疗并联合雄激素剥夺治疗,可能导致对根治治疗组治疗成功的过高估计,尤其考虑到两组无转移生存率和总生存率相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In older patients who do not wish to undergo watchful waiting, focal therapy could be an alternative to the more morbid radical treatment. We evaluated the role of focal therapy in patients 70 years and older as an alternative management modality. MATERIALS AND METHODS: A total of 649 patients across 11 UK sites receiving focal high-intensity focused ultrasound or cryotherapy between June 2006 and July 2020 reported within the UK-based HEAT (HIFU Evaluation and Assessment of Treatment) and ICE (International Cryotherapy Evaluation) registries were evaluated. Primary outcome was failure-free survival, defined by need for more than 1 focal reablation, progression to radical treatment, development of metastases, need for systemic treatment, or prostate cancer-specific death. This was compared to the failure-free survival in patients undergoing radical treatment via a propensity score weighted analysis. RESULTS: Median age was 74 years (IQR: 72, 77) and median follow-up 24 months (IQR: 12, 41). Sixty percent had intermediate-risk disease and 35% high-risk disease. A total of 113 patients (17%) required further treatment. Sixteen had radical treatment and 44 required systemic treatment. Failure-free survival was 82% (95% CI: 76%-87%) at 5 years. Comparing patients who had radical therapy to those who had focal therapy, 5-year failure-free survival was 96% (95% CI: 93%-100%) and 82% (95% CI: 75%-91%) respectively (P < .001). Ninety-three percent of those in the radical treatment arm had received radiotherapy as their primary treatment with its associated use of androgen deprivation therapy, thereby leading to potential overestimation of treatment success in the radical treatment arm, especially given the similar metastases-free and overall survival rates seen. CONCLUSIONS: We propose focal therapy to be an effective management option for the older or comorbid patient who is unsuitable for or not willing to undergo radical treatment.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Habashy D, Reddy D, Peters M, et al. Evaluation of Outcomes Following Focal Ablative Therapy for Treatment of Localized Clinically Significant Prostate Cancer in Patients >70 Years: A Multi-institute, Multi-energy 15-Year Experience. J Urol. 2023. PMID: 37014172. doi:10.1097/JU.0000000000003443

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。